Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Shares of Novartis AG (NYSE:NVS – Get Rating) have received a consensus recommendation of “Hold” from the sixteen ratings firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $84.75.
NVS has been the subject of several research reports. Kepler Capital Markets upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a CHF 90 price objective for the company in a report on Wednesday, September 7th. StockNews.com assumed coverage on shares of Novartis in a research report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Stifel Nicolaus raised shares of Novartis from a “hold” rating to a “buy” rating in a report on Monday, December 5th. Morgan Stanley lowered their price objective on shares of Novartis from CHF 97 to CHF 88 in a research note on Thursday, September 8th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Novartis from CHF 75 to CHF 70 and set a “sell” rating on the stock in a research note on Friday, October 7th.
Institutional Trading of Novartis
Several large investors have recently added to or reduced their stakes in NVS. Citigroup Inc. raised its position in shares of Novartis by 8.3% during the 1st quarter. Citigroup Inc. now owns 166,466 shares of the company’s stock worth $14,607,000 after acquiring an additional 12,745 shares in the last quarter. BlackRock Inc. grew its stake in shares of Novartis by 18.3% in the 1st quarter. BlackRock Inc. now owns 1,556,539 shares of the company’s stock valued at $136,587,000 after purchasing an additional 240,710 shares during the last quarter. Raymond James Trust N.A. grew its stake in shares of Novartis by 4.7% in the 1st quarter. Raymond James Trust N.A. now owns 20,099 shares of the company’s stock valued at $1,763,000 after purchasing an additional 901 shares during the last quarter. Banco de Sabadell S.A grew its stake in shares of Novartis by 8.0% in the 1st quarter. Banco de Sabadell S.A now owns 7,222 shares of the company’s stock valued at $631,000 after purchasing an additional 536 shares during the last quarter. Finally, Connolly Sarah T. boosted its stake in shares of Novartis by 2.2% in the first quarter. Connolly Sarah T. now owns 25,073 shares of the company’s stock valued at $2,200,000 after buying an additional 536 shares in the last quarter. 8.12% of the stock is currently owned by hedge funds and other institutional investors.
Novartis Price Performance
NVS stock opened at $90.72 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.31 and a quick ratio of 1.07. Novartis has a one year low of $74.09 and a one year high of $94.26. The stock has a market cap of $200.73 billion, a PE ratio of 9.32, a P/E/G ratio of 2.57 and a beta of 0.56. The firm has a 50 day simple moving average of $86.77 and a two-hundred day simple moving average of $83.56.
Novartis (NYSE:NVS – Get Rating) last announced its quarterly earnings data on Tuesday, October 25th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.01. The firm had revenue of $12.54 billion during the quarter, compared to analyst estimates of $12.90 billion. Novartis had a net margin of 42.66% and a return on equity of 20.89%. On average, analysts predict that Novartis will post 6.02 EPS for the current fiscal year.
About Novartis
(Get Rating)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
See Also
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It’s Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novartis, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Novartis wasn’t on the list.
While Novartis currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
